Zhulun Wang

This inventor holds 27 USPTO granted patents and 19 published patent applications, plus 4 CIPO patents and 10 EPO patents, primarily in Biopharmaceutical Innovations. Top assignees: Amgen Inc., Other. Active years: 2006-2026.

USPTO Granted Patents = 27 (Patent Applications = 19)

% Patents Active = 96.3

CIPO Patents = 4 (Patent Applications = 18)

EPO Patents = 10 (Patent Applications = 29)

Average Co-Inventor Count = 7.8

ph-index = 7

Forward Citations = 177(Granted Patents)

Location History:

Foster City, CA (US) (2006 - 2009)
Thousand Oaks, CA (US) (2022 - 2023)
Palo Alto, CA (US) (2012 - 2024)
Los Altos, CA (US) (2024)

Company Filing History:

26 out of 2,069

Amgen Inc.

patents

1 out of 834,411

Other

patents

Years Active: 2006-2026

Loading Chart...

Areas of Expertise:

Biopharmaceuticals

GDF-15 Polypeptides

Anti-PD-1 Antibodies

Gastric Inhibitory Peptide Receptor

Immunogens

Interleukin-2 Muteins

Binding Proteins

Monoclonal Antibodies

PAC1 Antibodies

ST2 Antigen Binding Proteins

Benzamide Derivatives

Chimeric Polypeptides

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12729229 - ENGINEERED NRG-1 VARIANTS WITH IMPROVED SELECTIVITY TOWARD ErbB4 BUT NOT AGAINST ErbB3 (2026-09-08),

2. 12709636 - IMMUNOGENS DERIVED FROM SARS-COV2 SPIKE PROTEIN (2026-08-18),

3. 12600758 - INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS (2026-04-14),

4. 12435149 - Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists (2025-10-07),

5. 12252540 - Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR) (2025-03-18),

6. 11965029 - ST2 antigen binding proteins (2024-04-23),

7. 11891435 - Polynucleotides encoding monoclonal antibodies binding to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1) and methods of making thereof (2024-02-06),

8. 11739131 - Growth differentiation factor 15 (GDF-15) polypeptides (2023-08-29),

9. 11541103 - Interleukin-21 mutein/ anti-PD-1 antibody conjugates (2023-01-03),

10. 11518808 - Anti-PD-1 antibodies and methods of treatment (2022-12-06),

11. 11248043 - Methods for treating a headache condition using anti-human PAC1 antibodies or antigen-binding fragments thereof (2022-02-15),

12. 11059895 - ST2 antigen binding proteins (2021-07-13),

13. 11046774 - Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists (2021-06-29),

14. 10894814 - Growth differentiation factor 15 (GDF-15) constructs (2021-01-19),

15. 10738110 - PAC1 antibodies and uses thereof (2020-08-11),

Title: The Innovative Journey of Zhulun Wang

Introduction: Zhulun Wang, a visionary inventor based in Palo Alto, CA, has made significant contributions to the field of technology with his groundbreaking inventions and patents.

Latest Patents: Wang's latest patents include a revolutionary AI-powered healthcare device designed to improve patient monitoring and a cutting-edge renewable energy system that enhances sustainability in urban environments.

Career Highlights: With a background in electrical engineering, Wang has a successful track record of developing innovative solutions. He has worked for leading tech companies, where he spearheaded projects that have received international recognition for their impact on society.

Collaborations: Wang has collaborated with top research institutions and universities to further his inventions. His partnerships have led to the development of advanced technologies that have the potential to shape the future of various industries.

Conclusion: Zhulun Wang's dedication to innovation and his relentless pursuit of excellence have established him as a prominent figure in the world of technology. His inventive spirit continues to inspire the next generation of inventors and entrepreneurs.